Gemtuzumab ozogamicin (GO) consists of an anti-CD33 antibody covalently linked to the cytotoxic compound calicheamicin.
/l. Following treatment a complete remission was diagnosed. Platelet recovery was complete (217 × 10 9 /l). The main side-effect was WHO grade 3 transaminase elevation, which resolved spontaneously. Matched unrelated stem cell transplantation (SCT) was performed 2 months after the last GO treatment. Six months after SCT she is in continuous complete remission with complete chimerism. No severe side-effects such as venoocclusive disease or hepatotoxicity have occurred.
UPN 2 was 3-month-old boy with a BCP ALL, with a t(4;11) translocation and myeloid antigen co-expression at diagnosis (Ͼ90% of the leukemic blasts positive for CD33 expression). Initially he was enrolled in the Interfant 99 protocol and entered the prednisone good responder arm. Despite rapid clearance of the blasts during induction as assessed by morphological methods, RT-PCR of the MLL-AF4 fusion gene and the MRD evaluation by the use of clonotypic immunoglobulins (Ig) and T cell receptor antigen gene (TcR) rearrangements were persistently positive during the first months of treatment. He relapsed 5 months from initial diagnosis. Only a 5/6 HLA-matched non-family cord blood donor unit was available, but two different courses of chemotherapy failed to induce even a partial remission. Treatment with GO, consisting of 9.0 mg/m 2 twice, with a 14 day interval, was given. Before the treatment with GO, the BM showed Ͼ90% leukemic blasts (IPT: CD3 negative (neg); CD10 neg; CD14 neg; CD15 84%, CD19 85%, CD33 90%, CD34 65%, HLA-DR 93%, karyotyping not performed), the WBC was 28 × 10 9 /l with more than 90% blasts. After 24 h the WBC count was 8.2 × 10 9 /l. At day 7 from the first GO infusion, the WBC was reduced to 0.5 × 10 9 /l. However, at day 14, when the second dose of GO was planned, a progressive re-growth of leukemia was observed and accordingly the drug was discontinued. GO was well tolerated and no major side-effects were observed in this patient.
UPN 3, a 3-year-old boy, was diagnosed with high risk BCP-ALL (diagnostic WBC 398 × 10 9 /l; IPT: CD10 94%, CD19 91%, CD22 88%, CD33 neg, CD34 neg, cyt. IgM 78%, HLA-DR95%; karyotype:45,XY,add(1),add(7)(q32q36),add(9)(p1),add(11)(q23),der(11) t(1;11)(p1;p11.2),add(12)(p11.2),−13; additional fluorescent in situ hybridization showed rearrangement of the MLL gene). He was treated with the MRC high risk ALL protocol and underwent sibling allogeneic SCT 6 months following diagnosis. Five months following SCT, he experienced a BM and testicular relapse, and he had reinduction chemotherapy with testicular radiotherapy. Thirteen months later he experienced an isolated central nervous system (CNS) relapse that was treated with further chemo-and radiotherapy. Twenty-eight months later, whilst on continuation therapy, he suffered a CNS and BM relapse. The blasts continued to be of L2 morphology, however, there was an immunophenotypic shift (CD10 44%, CD19 33%, CD33 35%, CD34 26%, CD45 100%; karyotype: not repeated). Although he was pancytopenic at relapse, his peripheral blast count rose over the subsequent 7 days to 2.5 × 10 9 /l. GO (7.5 mg/m 2 ) was administered as a single infusion without any adverse effects. Two days later no leukemic blasts were observed on his peripheral blood smear. No abnormal liver chemistry was observed. It was intended to repeat a further dose of GO at day 14 followed by marrow evaluation, but unfortunately the patient became progressively somnolent secondary to CNS leukaemic infiltration and died on day 12 post-GO administration.
The cellular resistance studies to single-agent calicheamicin (kindly provided by Wyeth-Ayerst Research) were performed at the Laboratory of Pediatric Oncology in Amsterdam. The calicheamicin concentration range was empirically defined to obtain optimal dose-response curves in AML samples, and ranged from 0.004 to 400 nanogram/ml, in line with the previously reported potency of these compounds. 4 We tested 22 newly diagnosed childhood AML samples (median WBC 54.6 × 10 9 /l; median age 3.9 years; FAB-type classification: one M0, one M1, six M2, six M4, six M5 and two unclassified), 12 newly diagnosed childhood ALL samples (median WBC 72.4 × 10 9 /l; median age 2.4 years; seven samples showed the TEL-AML gene rearrangement and two samples were T cell ALL, none were hyperdiploid; details are given in Table 1 ) and 16 normal, non-leukemic, bone marrow samples from healthy children undergoing elective surgery. The normal bone marrow mononuclear cells were tested after isolation by centrifugation on Ficoll density gradients. Sampling was done only after informed consent had been obtained and with IRB approval. Cellular resistance was studied using the MTT assay, as described elsewhere. 5 Results were expressed as LC 50 values, which is the concentration needed to kill 50% of the cells. We found large differences in resistance to calicheamicin between the individual samples. ALL cells were a median of Ͼ15 000-fold more sensitive (P Ͻ 0.001) to singleagent calicheamicin than normal non-leukemic bone marrow cells. ALL cells were also significantly more sensitive to single-agent calicheamicin than AML cells, although the difference was less marked (median Ͼ3500-fold, P = 0.001). Results are depicted in Figure 1 .
The cases presented here suggest that GO is able to induce responses in relapsed CD33-positive ALL. In the first patient a CR was obtained and the patient is in continuous complete remission after SCT. In the second patient a short-lived drop in WBC was documented where other regimens had failed completely. In the third patient a drop in WBC was found, but the response could not be assessed fully, due to progression of CNS disease. This also suggests that GO does not pass the blood-brain barrier, even in the case of frank CNS disease. So far, no other reports about GO treatment of CD33-positive ALL patients have been published. The phase I and II studies have been restricted to CD33-positive AML patients only. The responses that were documented in the three cases reported here may also be related to the extreme sensitivity of ALL cells to calicheamicin, as shown by the in vitro cellular resistance studies when ALL and AML cells were compared. This also suggests that the development of a calicheamicin conjugate linked to an anti-ALL antibody could potentially result in a very potent drug for ALL treatment. Such drugs are currently under development.
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Figure 1
Differences in single-agent calicheamicin resistance between AML, ALL and normal bone marrow cells. Normal bone marrow cells (BM) are significantly more resistant to single-agent calicheamicin than ALL cells (median Ͼ15 750-fold, P Ͻ 0.001). ALL cells are also significantly more sensitive to single-agent calicheamicin than AML cells (Ͼ3500-fold, P = 0.001). Results are given in LC 50 values (ng/ml). Each dot represents the LC 50 value for calicheamicin of an individual sample, the horizontal lines depict the median LC 50 values.
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TO THE EDITOR
A major cause of treatment failure in patients with acute myeloid leukemia (AML) is the occurrence of resistance to structurally and functionally unrelated drugs, called multidrug resistance (MDR). Several mechanisms of drug resistance have been identified; one of these is the overexpression of adenosine triphosphate (ATP)-dependent membrane proteins that function as drug efflux pumps. The best-characterized drug efflux pump is the permeability-glycoprotein (P-gp) which is encoded by the MDR1 gene. 1 Expression of MDR1 has been identified as an independent adverse prognostic factor for complete remission and survival in adult patients with AML. 1 Recent studies suggested that the results in the treatment of adult patients with AML can be improved by combining chemotherapy with drugs that inhibit the function of P-gp such as cyclosporine.
1,2 However, AML is a rare disease in children and so far, too few data on the clinical relevance of P-gp in childhood AML are available.
The aim of this study was to find out whether the expression of the MDR1 gene indicates a poor prognosis in childhood AML. If that was the case, it would provide evidence in favor of clinical trials with drugs that inhibit the function of P-gp in children with AML.
MDR1 gene expression was measured using TaqMan real time PCR in 58 children with de novo AML. Nine patients were also analyzed in relapse. In 15 patients, in vitro drug resistance was measured by methylthiazoltetrazolium (MTT) assays with cytarabine, daunorubicin, etoposide, vincristine and thioguanine.
The group of patients and the methods of sample collection, sample processing and real time PCR were all identical to our study on the expression of the breast cancer resistance protein (BCRP) which was recently published in this journal.
3 PCR primers and TaqMan probe for MDR1 amplification were used as described by Schiedlmeier et al. 4 The cell line CEM-ADR5000 was used to generate the standard curves. The regression coefficients ranged between 0.995 and 0.998. MTT assays were performed as described by Yamada et al. 5 Measurable amounts of MDR1 were found in all patient samples (Figure 1 ). The expression levels varied about 20-fold from the 10th percentile to the 90th percentile. Relative to the reference cell line CEM-ADR5000, which was selected because of its high expression of MDR1, the median expression of the patient samples was 0.0015. Three samples of CD34 + stem cells from healthy donors showed levels of MDR1 gene expression that were similar to the highest levels found in AML patients (median 0.011). No significant difference was found between the expression of MDR1 gene in four samples of bone marrow and four samples of peripheral blood from healthy donors. The expression in all of these eight samples was similar to the lowest levels that were found in AML patients (median 0.00047 in blood and 0.00042 in bone marrow).
Forty patients achieved remission and 18 did not. The distribution of MDR1 gene expression in both groups was very similar.
When using the 25th, the 50th or the 75th percentile of MDR1 gene expression as cutoff for high and low expression we found no significant difference in overall survival between the groups. The Kaplan-Maier estimate for overall survival was even higher in patients whose MDR1 gene expression levels were higher than the median as compared to patients with low levels of MDR1 (Figure 2 ). It therefore seems very unlikely that high expression of the MDR1 gene could be found to be an indicator of a significantly worse prognosis in larger studies. The results were similar when relapse-free survival was calculated instead of overall survival.
Sievers et al 6 measured the expression of P-gp in 130 children with de novo AML by flow cytometry. Dahl et al 7 studied the expression of MDR1 (RT-PCR) and P-gp (flow cytometry) in 59 children with relapsed or refractory AML. Both groups found no prognostic implication of P-gp. Those two studies and our results provide supplementing information. Together, they strongly suggest that the expression of the MDR1 gene and its product, P-gp, do not define a poor prognostic group in childhood AML.
MDR1 gene expression was unevenly distributed among the different FAB types (Kruskal-Wallis test P = 0.004) with high levels in M1 and M2 and low levels in M4 and M5. Median expression of MDR1 was four-fold higher in patients with Auer rods than in patients without (Mann-Whitney test P < 0.0001) and also four-fold higher in patients with the translocation t(8;21) than in patients without this translocation (Mann-Whitney test P = 0.002; Figure 1 ). The latter correlation was also described by Pearson et al 8 in a series of 20 pediatric AML samples. We also found an inverse correlation between MDR1 gene expression and initial white blood count (P = 0.003; Spearman's correlation coefficient −0.39).
These findings suggest that the expression of MDR1 is higher in children with favorable subgroups of AML. In our study on the expression of BCRP in childhood AML we found a very similar pattern of expression, 3 but we could also show that high levels of BCRP indicated a poor prognosis when comparing patients with otherwise similar risk factors.
We were not able to demonstrate such an association between MDR1 gene expression and prognosis. However, in larger studies it could possibly be found that MDR1 gene, like BCRP, is expressed at higher levels in favorable subgroups of pediatric AML but indicates a poor prognosis within each subgroup.
In 15 patients we analyzed in vitro drug resistance to cytarabine, adriamycin, etoposide, vincristine and thioguanine by means of MTT assays. Only resistance to vincristine, which is probably the least important of those five drugs in the treatment of childhood AML, was associated with a high expression of MDR1 (Spearman's correlation coefficient 0.62; P = 0.032). Although the absence of a correlation with resistance to the other four drugs might be attributed to the small number of patients, this finding also suggests that MDR1 is not the major cause of drug resistance in childhood AML. Den Boer et al
